SPSB2

Across TCGA pan-cancer cohorts, SPSB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPSB2 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPSB2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPSB2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where SPSB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.976	0.414	.011	9	view →
LSCC	OS	Median	All	0.660	1.000	.021	6	view →
CCRCC	DFS	Quartile	All	1.000	0.523	.049	3	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.540	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPSB2–LUAD (DFS)

Open the LUAD breakdown →